Heterotypic cellular interactions in the ovarian tumor microenvironment: biological significance and therapeutic implications

被引:12
作者
Naora, Honami [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
ovarian cancer; tumor microenvironment; mesothelium; endothelial cells; adipocytes; fibroblasts; mesenchymal stem cells; macrophages;
D O I
10.3389/fonc.2014.00018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of women who are diagnosed with epithelial ovarian cancer present with extensive peritoneal carcinomatosis and are rarely cured by conventional chemotherapy. Ovarian cancer cells typically disseminate by shedding into the peritoneal fluid and implant on the mesothelium-lined peritoneal surfaces that overlie connective and white adipose tissues. Emerging evidence indicates that ovarian tumor progression is orchestrated by dynamic interplay between tumor cells and a variety of stromal cells such as adipocytes, endothelial cells, fibroblasts, mesenchymal stem cells, macrophages, and other immune cells. This mini -review discusses the biological significance of the heterotypic cellular interactions in the ovarian tumor microenvironment and the therapeutic implications of targeting these interactions.
引用
收藏
页数:7
相关论文
共 79 条
[1]   Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[2]   OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].
Aghajanian, Carol ;
Blank, Stephanie V. ;
Goff, Barbara A. ;
Judson, Patricia L. ;
Teneriello, Michael G. ;
Husain, Amreen ;
Sovak, Mika A. ;
Yi, Jing ;
Nycum, Lawrence R. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045
[3]   Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production [J].
Allavena, P ;
Signorelli, M ;
Chieppa, M ;
Erba, E ;
Bianchi, G ;
Marchesi, F ;
Olimpio, CO ;
Bonardi, C ;
Garbi, A ;
Lissoni, A ;
de Brand, F ;
Jimeno, J ;
D'Incalci, M .
CANCER RESEARCH, 2005, 65 (07) :2964-2971
[4]  
Alvarez AA, 1999, CLIN CANCER RES, V5, P587
[5]  
Amemori Sadahiro, 2007, Am J Physiol Gastrointest Liver Physiol, V292, pG923
[6]   Strategies for TGF-β modulation: a review of recent patents [J].
Bonafoux, Dominique ;
Lee, Wen-Cherng .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (12) :1759-1769
[7]   Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies [J].
Bottsford-Miller, Justin N. ;
Coleman, Robert L. ;
Sood, Anil K. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) :4026-4034
[8]   Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug [J].
Brennen, W. Nathaniel ;
Rosen, D. Marc ;
Wang, Hao ;
Isaacs, John T. ;
Denmeade, Samuel R. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (17) :1320-1334
[9]   Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study [J].
Burger, Robert A. ;
Sill, Michael W. ;
Monk, Bradley J. ;
Greer, Benjamin E. ;
Sorosky, Joel I. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5165-5171
[10]   Overview of anti-angiogenic agents in development for ovarian cancer [J].
Burger, Robert A. .
GYNECOLOGIC ONCOLOGY, 2011, 121 (01) :230-238